NorthWest Biotherapeutics Inc (NWBO): Wow—thanks! I have been so focused on...

Reply Private New

Next 10 Prev Next

SkyLimit2022

Send PM Follow Ignore

Followers	54
Posts	1662
Boards Moderated	0
Alias Born	04/22/2022

SkyLimit2022

Re: ATLnsider post# 650427

Friday, 11/24/2023 4:48:01 PM

Friday, November 24, 2023 4:48:01 PM

Wow—thanks!

I have been so focused on the amazing interim data from the DCVax-L PD-1 combo study at UCLA that I have not paid much attention to all of the other emerging possibilities …

The JCI article was enlightening, and then the Daiichi Sankyo news was intriguing as well!

Around the time that the DCVax-L P3 JAMA peer review was published, I had never heard of CSF-1R inhibitors or ADCs.

The field of cell-based therapy is evolving rapidly and the DCVax-L platform might be a key component for unlocking the efficacy of more than one class of drugs.

Adding CSF-1R to PD-1 blockade and DCVax-L is a combo that UCLA plans to study with the support of the NIH, and Merck seems to be on the cutting edge with their recently announced landmark partnership with Daiichi Sankyo. I would love to see Dr. Liau and Northwest Bio partner with Merck—the pembrolizumab combo study interim results bode well for the possibility of other efficacious combos with DCVax-L as a platform technology.

https://www.cell.com/trends/cancer/fulltext/S2405-8033(23)00005-5

https://www.jci.org/articles/view/169314

Bullish

Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.